Tirzepatide

Also known as: Mounjaro, Zepbound

Weight Loss FDA Approved

GLP-1/GIP dual receptor agonist

Mechanism of Action

Activates both GLP-1 and GIP receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting satiety.

3,333
Community Posts
648
Users Discussing
477
Research Articles

Reported Outcomes

Clinical Strength: A (245 trials)

Based on community reports (3,333 posts). Grade reflects frequency and consistency of positive mentions.

B Weight Loss
323 mentions

Reduction in body weight

B Sleep Quality
273 mentions

Effects on sleep quality

B Appetite Suppression
185 mentions

Reduced hunger and food cravings

C Blood Sugar Control
160 mentions

Improved glycemic control and insulin sensitivity

C Energy Levels
117 mentions

Changes in energy and fatigue levels

C GI Health
111 mentions

Gastrointestinal effects

C Mental/Mood
79 mentions

Effects on mood and cognitive function

D Body Composition
55 mentions

Changes in muscle vs fat ratio

D Cardiovascular
45 mentions

Effects on heart health markers

Side Effects

Based on 804 user reports. Frequency indicates how often each was mentioned.

Common (>5%)

Fatigue
Mild 123 reports 10.2%
Constipation
Mild 102 reports 8.5%
Nausea
Mild 89 reports 7.4%

Uncommon (1-5%)

Stinging
Mild 59 reports 4.9%
Insomnia
Mild 41 reports 3.4%
Injection Site Reaction (Isr)
Mild 35 reports 2.9%
Hair Loss
Mild 31 reports 2.6%
Tiredness
Mild 30 reports 2.5%
Burning
Mild 30 reports 2.5%
Food Noise
Mild 30 reports 2.5%
Chills
Mild 25 reports 2.1%
Diarrhea
Mild 24 reports 2.0%
Acid Reflux
Mild 22 reports 1.8%
Water Retention
Mild 19 reports 1.6%
Heartburn
Mild 19 reports 1.6%
Exhaustion
Mild 17 reports 1.4%
Increased Hunger
Mild 16 reports 1.3%
Injection Site Pain
Mild 16 reports 1.3%
Allodynia (Skin Sensitivity)
Mild 15 reports 1.2%
Gerd
Mild 14 reports 1.2%

Risks & Warnings

Important safety considerations based on clinical data and community reports.

!

Pancreatitis

15 mentions

Rare but serious. Stop medication and seek care for severe persistent abdominal pain.

!

Gallbladder Issues

19 mentions

Rapid weight loss increases gallstone risk. Report severe abdominal pain to healthcare provider.

!

Thyroid Concerns

12 mentions

GLP-1 agonists carry a boxed warning for thyroid C-cell tumors in rodents. Contraindicated in MEN2 or personal/family history of MTC.

!

Hypoglycemia Risk

13 mentions

Risk increases when combined with insulin or sulfonylureas. Monitor blood sugar carefully.

!

Psychiatric Effects

13 mentions

Monitor for mood changes. Report any concerning psychiatric symptoms to healthcare provider.

!

Muscle Loss

10 mentions

Rapid weight loss may include muscle. Adequate protein intake and resistance training recommended.

!

Hair Loss

7 mentions

May occur with rapid weight loss. Usually temporary (telogen effluvium). Ensure adequate nutrition.

i

Gastrointestinal Issues

128 mentions

GI side effects are the most commonly reported. Usually improve over time with slow titration.

i

Injection Site Reactions

53 mentions

Local reactions are common and usually mild. Rotate injection sites.

Dosing

Standard Protocol

Starting Dose
2.5mg weekly
Titration
Increase by 2.5mg every 4 weeks as tolerated
Half-life
~5 days
Administration
Subcutaneous injection, once weekly

Community Dosing Patterns

Based on 1616 mentions

Community-reported patterns, not medical advice.

5mg weekly
140
2.5mg weekly
106
10mg weekly
101
7.5mg weekly
99
15mg weekly
69

Pricing

Research-grade reference pricing for 10mg vial. Prices vary by vendor and quantity.

We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.

US Research Grade

$100

Single small vial from US domestic vendors

US Research Grade (Bulk)

$50

Per-dose equivalent when buying larger US vials

China Research Grade

$2.85

Per-vial when buying 10-pack from Chinese vendors

97% savings

Research

477
Total Articles
245
Clinical Trials
198
Reviews

Key Studies

Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis meta_analysis

Metabol Open (2023)

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program meta_analysis

Cardiovasc Diabetol (2023)

The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes Other

Patient Prefer Adherence (2023)

Pharmacotherapy of obesity: an update on the available medications and drugs under investigation Review

EClinicalMedicine (2023)

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials meta_analysis

BMJ (2023)

Commonly Stacked With

Based on 3,333 community posts mentioning Tirzepatide.

Retatrutide 410 mentions (12.3%)
Semaglutide 352 mentions (10.6%)
Cagrilintide 99 mentions (3%)
BPC-157 36 mentions (1.1%)
Tesamorelin 34 mentions (1%)

Switching Patterns

Based on 300 discussions about switching to or from Tirzepatide.

→ Switching FROM

Semaglutide 26 mentions
Retatrutide 24 mentions

Users who switched to Tirzepatide

← Switching TO

Retatrutide 50 mentions
Semaglutide 15 mentions
Cagrilintide 10 mentions

Users who switched from Tirzepatide

Frequently Asked Questions

What is tirzepatide?

Does tirzepatide help with weight loss?

How much weight loss can be expected from tirzepatide?

Which is more effective for weight loss: tirzepatide or semaglutide?

Does tirzepatide reduce appetite?